Anthony W Tolcher

16PUBLICATIONS
183CO-AUTHORS
Molecular targetsTumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)AvionicsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Feb 22, 2026
Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors.

Jong Chul Park, David Berz, Manish R Sharma

|Feb 10, 2026
An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid Tumors.

Jatinder Kaur Mukker, Timothy A Yap, Anthony W Tolcher

|Jan 27, 2026
Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients With Select Solid Tumors.

Jong Chul Park, David Berz, Manish R Sharma

|Jan 27, 2026
Correlative Biomarker Analysis of PSMA Expression on CTCs and PSMA Imaging in a Phase I Study of PSMA-Targeted Tubulysin Conjugate EC1169.

Samir Zaidi, Phillip H Kuo, Tiago Paiva Prudente

|Aug 28, 2025
A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors.

Lillian L Siu, Timothy A Yap, Sofia Genta

|Sep 17, 2024
A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer.

Daniel Morgensztern, Neal Ready, Melissa L Johnson

Pageof 3